Repligen to Report Fourth Quarter and Full Year 2012 Financial Results

Repligen to Report Fourth Quarter and Full Year 2012 Financial Results

Webcast and Conference Call to be Held Thursday, March 7, 9:00 a.m. EST

WALTHAM, Mass., March 1, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation
(Nasdaq:RGEN) announced today that it will report financial results for the
fourth quarter and year ended December 31, 2012 on March 7. On this date, the
Company will issue a press release prior to the opening of the NASDAQ Global
Market, followed by a conference call and webcast at 9:00 a.m. EST to discuss
financial results for the reporting period. The event will be hosted by Walter
C. Herlihy, Ph.D., President and CEO of Repligen.

Repligen's fourth quarter and year end conference call will be accessible by
dialing (800) 291-5365 for domestic callers or (617) 614-3922 for
international callers. Dial-in participants must provide the passcode
66969032. Alternatively, an audio webcast will be accessible via the Investors
section of Repligen's website www.repligen.com. Both the conference call and
webcast will be archived for a period of time following the live event. The
replay dial-in numbers are (888) 286-8010 for domestic callers and (617)
801-6888 for international callers. Replay listeners must provide the passcode
97774715.

About Repligen Corporation

Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the
development, production and commercialization of high-value consumable
products used in the process of manufacturing biological drugs. Our
bioprocessing products are sold to major life sciences and biopharmaceutical
companies worldwide. We are a leading manufacturer of Protein A, a critical
reagent used to separate and purify monoclonal antibody therapeutics. We also
supply several growth factor products used to increase cell culture
productivity during the fermentation stage of drug manufacturing. In addition,
we have developed and market our OPUS® series of pre-packed "plug-and-play"
chromatography columns, and we provide test kits to ensure final product
quality. Aside from our core bioprocessing business, we have a portfolio of
clinical-stage partnering assets, including a pancreatic imaging agent in
Phase 3 development and a orphan drug candidate in Phase 1 development.
Repligen's corporate headquarters are located in Waltham, MA (USA) and our
manufacturing facilities are located in Waltham, MA and Lund, Sweden.

This press release may contain forward-looking statements within the meaning
of the federal securities laws. Investors are cautioned that statements in
this press release which are not strictly historical statements including,
without limitation, statements identified by words like "believe," "expect,"
"may," "will," "should," "seek," or "could" and similar expressions,
constitute forward-looking statements. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including risks discussed from
time to time in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.

CONTACT: Repligen Corporation
         Sondra Newman
         Director Investor Relations
         (781) 419-1881
         snewman@repligen.com
 
Press spacebar to pause and continue. Press esc to stop.